Bulls HW, et al. - In this investigation, researchers assessed longitudinal change in patient-reported chemotherapy-induced peripheral neuropathy (CIPN) symptoms from the start of chemotherapy to one year post-chemotherapy as well as treatment modifications in older (≥65 years) and younger patients (<65 years). Among 90 gynecologic cancer patients treated with cytoxic chemotherapy during the active treatment phase, older and younger patients reported comparable increases in CIPN, but older patients did not recover from CIPN following completion of treatment, while younger patients showed significant reductions in post-treatment CIPN symptoms. For chronic CIPN symptoms, older survivors might require additional education and treatment, since they were at higher risk for chronic CIPN. Findings revealed no age differences in the presence of provider-recorded sensory neuropathy and pain; neuropathy-related treatment delays, changes in chemotherapy dose, regimen, or discontinuations; or falls.